Coming on the heels of the Hims & Hers confrontation and the September 2025 cease-and-desist campaign, these letters establish a clear trajectory: the FDA intends to use the full range of its enforcement authority to curtail what it views as misleading marketing of compounded drugs that circumvent the approval process
And if you still dont see any liquid after that, contact us and well help you
This includes those who: Have heart disease, kidney problems, or overweight Want to avoid weight gain or low blood sugar from other diabetes medicines People with overweight or obesity, including: Adults with a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher and at least one weight-related health problem (such as high blood pressure or sleep apnea) Adults who have not met weight-loss goals with lifestyle changes alone Adolescents with obesity who qualify for certain GLP-1 medications Who should not receive GLP-1 medications
By understanding the challenges and implementing strategic formulation and packaging practices, formulators can create products that harness the full potential of these powerful peptides
reported that the five most common symptoms of hospitalized patients were fatigue (28.4%), pain/discomfort (27.9%), sleep difficulties (23.5%), breathlessness (22.6%), and limited regular activity (22.3%)
